Anapril Drug Interactions

Antihypertensive Therapy: Additive effect may occur when Anapril is used together with other antihypertensive therapy.
Serum Potassium: In clinical trial, serum potassium usually remained within normal limits. In hypertensive patients treated with Anapril alone for up to 48 weeks, mean increases in serum potassium of approximately 0.2 mEq/L were observed. In patients treated with Anapril plus a thiazide diuretic, the potassium losing effects of the diuretic was attenuated usually by the effect of enalapril.
If Anapril is given with a potassium-losing diuretic, diuretic-induced hypokalemia may be ameliorated.
Risk factors for the development of hyperkalemia include renal insufficiency, diabetes mellitus and concomitant use of potassium-sparing diuretics (eg, spironolactone, triamterene or amiloride), potassium supplements or potassium-containing salt substitutes. The use of potassium supplements, potassium-sparing diuretics or potassium-containing salt substitutes particularly in patients with impaired renal function may lead to a significant in serum potassium.
If concomitant use of previously-mentioned agents is deemed appropriate, they should be used with caution and with frequent monitoring of serum potassium.
Serum Lithium: As with other drugs which eliminate sodium, lithium clearance may be reduced. Therefore, the serum lithium levels should be monitored carefully if lithium salts are to be administered.